Sign inJoin waitlistJoin the waitlist

Claudia Fox

Associate Program Director · University of Minnesota

Credentials: · · · ·

History

Pediatrics
1995–1998
University of Minnesota Medical School
1991–1995

Research

The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial
JAMA Pediatrics · 2013 · 147 citations
Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study
Obesity · 2012 · 115 citations
Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
Review · Obesity · 2019 · 104 citations

Eric Bomberg
15 papers · 4 as a resident
Megan Bensignor
14 papers
Carolyn Bramante
11 papers · 2 as a resident
Brandon Nathan
7 papers
MS
Muna Sunni
4 papers · 2 as a fellow
RH
Robert Hebbel
4 papers
Sarah Raatz
4 papers
Sarah Schwarzenberg
4 papers
AS
Ashley Shoemaker
3 papers
Marc Michalsky
3 papers
MA
Mary Abuzzahab
3 papers
Sarah Armstrong
3 papers · 2 as a resident

Grants

Toward Repurposing a Commonly-Used Medication for the Treatment of Pediatric Severe Obesity
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $914.9K · University of Minnesota
2023–2027
SMART Use of Medication for the Treatment ofAdolescent Severe Obesity
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $3.2M · University of Minnesota
2019–2025

Clinical trials

Vyvanse in Children Aged 6 to 12 Years
Principal investigator · Completed · Early phase 1
University of Minnesota
2023–2026
SMART Use of Medication for the Treatment of Adolescent Severe Obesity
Principal investigator · Completed · Phase 2
University of Minnesota
2019–2025
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Site PI · Not yet recruiting · Phase 3
Eli Lilly and Company
2026–2032
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2024–2027